Katherine A Grosset

Summary

Country: UK

Publications

  1. pmc Effect of educational intervention on medication timing in Parkinson's disease: a randomized controlled trial
    Katherine A Grosset
    Department of Neurology, Institute of Neurological Sciences, Southern General Hospital, Glasgow, UK
    BMC Neurol 7:20. 2007
  2. doi request reprint Accuracy of Parkinson's disease diagnosis in 610 general practice patients in the West of Scotland
    Edward J Newman
    Department of Neurology, Institute of Neurological Sciences, Southern General Hospital, Glasgow, UK
    Mov Disord 24:2379-85. 2009
  3. pmc Variation in Recent Onset Parkinson's Disease: Implications for Prodromal Detection
    Diane M A Swallow
    Department of Neurology, Institute of Neurological Sciences, Glasgow, UK
    J Parkinsons Dis 6:289-300. 2016
  4. ncbi request reprint Two-year follow-up in 150 consecutive cases with normal dopamine transporter imaging
    Vicky L Marshall
    Department of Neurology, Institute of Neurological Sciences, Southern General Hospital, Glasgow, UK
    Nucl Med Commun 27:933-7. 2006
  5. pmc Vascular disease and vascular risk factors in relation to motor features and cognition in early Parkinson's disease
    Naveed Malek
    Department of Neurology, Institute of Neurological Sciences, Queen Elizabeth University Hospital, Glasgow, United Kingdom
    Mov Disord 31:1518-1526. 2016
  6. ncbi request reprint Suboptimal medication adherence in Parkinson's disease
    Katherine A Grosset
    Institute of Neurological Sciences, Southern General Hospital, Glasgow, United Kingdom
    Mov Disord 20:1502-7. 2005
  7. pmc Statins are underused in recent-onset Parkinson's disease with increased vascular risk: findings from the UK Tracking Parkinson's and Oxford Parkinson's Disease Centre (OPDC) discovery cohorts
    Diane M A Swallow
    Department of Neurology, Institute of Neurological Sciences, Glasgow, UK
    J Neurol Neurosurg Psychiatry 87:1183-1190. 2016
  8. doi request reprint Prescription of drugs with potential adverse effects on cardiac conduction in Parkinson's disease
    Naveed M Malek
    Department of Neurology, Institute of Neurological Sciences, Ward 67, Southern General Hospital, Glasgow G51 4TF, UK
    Parkinsonism Relat Disord 19:586-9. 2013
  9. ncbi request reprint Medicine-taking behavior: implications of suboptimal compliance in Parkinson's disease
    Katherine A Grosset
    Department of Neurology, Institute of Neurological Sciences, Southern General Hospital, Glasgow, United Kingdom
    Mov Disord 20:1397-404. 2005
  10. doi request reprint Inhaled apomorphine in patients with 'on-off' fluctuations: a randomized, double-blind, placebo-controlled, clinic and home based, parallel-group study
    Katherine A Grosset
    Department of Neurology, Institute of Neurological Sciences, Southern General Hospital, Glasgow, UK
    J Parkinsons Dis 3:31-7. 2013

Collaborators

Detail Information

Publications16

  1. pmc Effect of educational intervention on medication timing in Parkinson's disease: a randomized controlled trial
    Katherine A Grosset
    Department of Neurology, Institute of Neurological Sciences, Southern General Hospital, Glasgow, UK
    BMC Neurol 7:20. 2007
    ..The effect of informing Parkinson's disease patients about the continuous dopaminergic hypothesis (to encourage regular medicine intake) on medication adherence and motor control was tested...
  2. doi request reprint Accuracy of Parkinson's disease diagnosis in 610 general practice patients in the West of Scotland
    Edward J Newman
    Department of Neurology, Institute of Neurological Sciences, Southern General Hospital, Glasgow, UK
    Mov Disord 24:2379-85. 2009
    ..Nearly all of these patients can be identified by simple screening of prescription databases and case records in Primary Care, followed by clinical review, which allows withdrawal of unnecessary medication...
  3. pmc Variation in Recent Onset Parkinson's Disease: Implications for Prodromal Detection
    Diane M A Swallow
    Department of Neurology, Institute of Neurological Sciences, Glasgow, UK
    J Parkinsons Dis 6:289-300. 2016
    ..The detection of prodromal Parkinson's disease (PD) is desirable to test drugs with neuroprotective potential, but will be affected by known disease variations...
  4. ncbi request reprint Two-year follow-up in 150 consecutive cases with normal dopamine transporter imaging
    Vicky L Marshall
    Department of Neurology, Institute of Neurological Sciences, Southern General Hospital, Glasgow, UK
    Nucl Med Commun 27:933-7. 2006
    ....
  5. pmc Vascular disease and vascular risk factors in relation to motor features and cognition in early Parkinson's disease
    Naveed Malek
    Department of Neurology, Institute of Neurological Sciences, Queen Elizabeth University Hospital, Glasgow, United Kingdom
    Mov Disord 31:1518-1526. 2016
    ..The purpose of this study was to examine the relationship between vascular disease (and vascular risk factors), cognition and motor phenotype in Parkinson's disease (PD)...
  6. ncbi request reprint Suboptimal medication adherence in Parkinson's disease
    Katherine A Grosset
    Institute of Neurological Sciences, Southern General Hospital, Glasgow, United Kingdom
    Mov Disord 20:1502-7. 2005
    ..In conclusion, poorer compliance is associated with younger age, depression, and more tablets per day, and one-fifth of PD patients underuse medication. Consideration of drug therapy adherence has implications in the management of PD...
  7. pmc Statins are underused in recent-onset Parkinson's disease with increased vascular risk: findings from the UK Tracking Parkinson's and Oxford Parkinson's Disease Centre (OPDC) discovery cohorts
    Diane M A Swallow
    Department of Neurology, Institute of Neurological Sciences, Glasgow, UK
    J Neurol Neurosurg Psychiatry 87:1183-1190. 2016
    ..It is less clear whether cardiovascular risk factors influence PD phenotype, and if statins are prescribed appropriately...
  8. doi request reprint Prescription of drugs with potential adverse effects on cardiac conduction in Parkinson's disease
    Naveed M Malek
    Department of Neurology, Institute of Neurological Sciences, Ward 67, Southern General Hospital, Glasgow G51 4TF, UK
    Parkinsonism Relat Disord 19:586-9. 2013
    ..This has implications in the management of Parkinson's disease, as commonly prescribed drugs for non-motor symptoms and comorbidities have QT prolonging potential...
  9. ncbi request reprint Medicine-taking behavior: implications of suboptimal compliance in Parkinson's disease
    Katherine A Grosset
    Department of Neurology, Institute of Neurological Sciences, Southern General Hospital, Glasgow, United Kingdom
    Mov Disord 20:1397-404. 2005
    ..Although the benefits of regularizing oral medicine-taking in a practical, achievable way in PD remain untested, such an approach might prolong and smooth the benefits of oral medication and is worthy of further research...
  10. doi request reprint Inhaled apomorphine in patients with 'on-off' fluctuations: a randomized, double-blind, placebo-controlled, clinic and home based, parallel-group study
    Katherine A Grosset
    Department of Neurology, Institute of Neurological Sciences, Southern General Hospital, Glasgow, UK
    J Parkinsons Dis 3:31-7. 2013
    ..In later stages of Parkinson's disease, treatment of 'off' periods with subcutaneous apomorphine is helpful but requires injection; inhaled apomorphine would be potentially more convenient...
  11. doi request reprint Geographical difference in Parkinson's disease prevalence within West Scotland
    Edward J Newman
    University of Glasgow, Department of Neurology, Institute of Neurological Sciences, Southern General Hospital, Glasgow, United Kingdom
    Mov Disord 24:401-6. 2009
    ..Exploration of these factors is justified to explain further such wide variation in PD prevalence...
  12. ncbi request reprint Successful antiparkinsonian medication withdrawal in patients with Parkinsonism and normal FP-CIT SPECT
    Vicky L Marshall
    Department of Neurology, Institute of Neurological Sciences, Southern General Hospital, Glasgow, United Kingdom
    Mov Disord 21:2247-50. 2006
    ..Such cases represent a nondegenerative form of Parkinsonism, which does not benefit from dopaminergic therapy. Prospective vigilance regarding this category is of importance in clinical practice and clinical trials...
  13. ncbi request reprint Patient-perceived involvement and satisfaction in Parkinson's disease: effect on therapy decisions and quality of life
    Katherine A Grosset
    Institute of Neurological Sciences, Southern General Hospital, Glasgow, United Kingdom
    Mov Disord 20:616-9. 2005
    ..Due attention to these aspects in delivering care to the PD patient is appropriate...
  14. pmc Tracking Parkinson's: Study Design and Baseline Patient Data
    Naveed Malek
    Department of Neurology, Institute of Neurological Sciences, Southern General Hospital, Glasgow, UK
    J Parkinsons Dis 5:947-59. 2015
    ..There is wide variation in the phenotypic expression of Parkinson's disease (PD), which is driven by both genetic and epidemiological influences...
  15. doi request reprint Switch from abobotulinumtoxinA (Dysport®) to incobotulinumtoxinA (Xeomin®) botulinum toxin formulation: a review of 257 cases
    Donald G Grosset
    Institute of Neurological Sciences, Southern General Hospital, G51 4TF Glasgow, United Kingdom
    J Rehabil Med 47:183-6. 2015
    ..To explore the dose equivalence ratio and treatment costs for abobotulinumtoxinA and incobotulinumtoxinA for patients with focal dystonias...
  16. ncbi request reprint Problematic gambling on dopamine agonists: Not such a rarity
    Katherine A Grosset
    Institute of Neurological Sciences, Southern General Hospital, Glasgow, Scotland
    Mov Disord 21:2206-8. 2006
    ..Thus, 8% of patients taking dopamine agonists had pathological gambling. Pathological gambling is not uncommon, and patients should be made aware of this potential adverse effect...